Avadel appoints Susan Rodriguez as COO; base salary $510K, 300K options

AVADEL PHARMACEUTICALS PLC

Susan Rodriguez appointed as COO effective May 13, 2025; role is newly created.
Base salary $510K, bonus potential 45% of salary, stock options for 300,000 shares vesting over 4 years.
Previously served as Chief Commercial Officer at Ardelyx and CEO at Tolmar Pharmaceuticals.
Appointment comes during LUMRYZ launch for narcolepsy; potential label expansion to idiopathic hypersomnia.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Susan Rodriguez

Chief Operating Officer

AVADEL PHARMACEUTICALS PLC

Effective: 2025-05-13
Filed: May 13, 2025, 7:59 PM ET

Effective May 13, 2025, the Board of Directors (the “Board”) of Avadel Pharmaceuticals plc (the “Company”) appointed Susan Rodriguez as the Company’s Chief Operating Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Susan Rodriguez was appointed as Chief Operating Officer at AVADEL PHARMACEUTICALS PLC.

Action: appointed
Role: Chief Operating Officer

Exact text from the filing

Effective May 13, 2025, the Board of Directors (the “Board”) of Avadel Pharmaceuticals plc (the “Company”) appointed Susan Rodriguez as the Company’s Chief Operating Officer.

View on SEC.gov

Source: SEC EDGAR

accession 0001104659-25-047848

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.